What PEARL Actually Changes in Clinical Practice

At a glance

Detail	Value
Trial name	PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity)
N	114
Intervention	Rapamycin (sirolimus) 5 mg or 10 mg once weekly
Comparator	Placebo
Duration	48 weeks
Primary endpoint	Self-reported health domains, immune markers, biomarkers of aging
Key result	Domain-specific quality-of-life improvements; no serious adverse events attributable to rapamycin at either dose

Why this trial generated so much noise

Rapamycin has extended lifespan in nearly every model organism tested, from yeast to mice. The Interventions Testing Program showed consistent mouse lifespan extension across three independent labs. Longevity clinicians have prescribed it off-label for years, largely on the strength of animal data and mechanistic reasoning about mTOR inhibition. What was missing until PEARL was a properly randomized, placebo-controlled trial in healthy humans asking a simple question: does this do anything measurable, and does it hurt anyone?

Published in Aging Cell in 2024, PEARL enrolled 114 generally healthy adults aged 50 to 85 and randomized them to rapamycin 5 mg/week, 10 mg/week, or placebo over 48 weeks. The trial was partly crowdfunded and run with a participatory design, meaning participants were actively engaged in the research process. That design choice matters for interpreting results.

What the methodology actually looked like

PEARL was a three-arm, double-blind, placebo-controlled trial. Participants were recruited through longevity-focused communities, which introduces a self-selection issue worth flagging. These were health-motivated adults, many already tracking biomarkers, taking supplements, and engaging in structured exercise. They are not a representative sample of the general 50-to-85 population.

The dosing schedule (once weekly, not daily) was chosen to mimic the intermittent mTOR inhibition protocol that showed immune benefits in the Mannick et al. 2014 study of the rapalog everolimus in older adults. Weekly dosing keeps trough levels low, theoretically suppressing mTORC1 while allowing mTORC2 to recover. This distinction matters because chronic daily rapamycin at transplant doses (2 to 5 mg/day) causes well-documented metabolic side effects: dyslipidemia, glucose intolerance, and mouth ulcers. The FDA label for sirolimus lists these prominently in the context of immunosuppression for organ transplant recipients.

The primary endpoints were composites. Self-reported health was measured across multiple domains. Immune markers included standard panels. "Biomarkers of aging" encompassed a range of blood-based measures. The trial was not powered for any single hard endpoint like infection rate, hospitalization, or mortality. This is the most important methodological limitation. Everything downstream of it must be interpreted accordingly.

The HealthRX.com Clinical Translation Framework for PEARL

We evaluate every longevity trial against four questions before deciding what, if anything, it changes at the point of care.

1. Did it move a hard endpoint? No. PEARL measured self-reported outcomes and surrogate biomarkers. No reduction in infections, fractures, hospitalizations, cancer incidence, or mortality was demonstrated. Self-reported quality-of-life improvements in specific domains are real data, but they sit low on the evidence hierarchy for changing prescribing behavior.

2. Was the safety signal clean enough for off-label use? Mostly yes, with caveats. PEARL reported no serious adverse events attributable to rapamycin at either dose. Mouth ulcers, the most common complaint in transplant-dose rapamycin use, occurred at low rates. Lipid panels and glucose markers did not show clinically meaningful deterioration at 48 weeks. This is genuinely useful data. Prior to PEARL, clinicians prescribing weekly rapamycin were relying on transplant-dose safety data (not applicable) and mouse pharmacokinetics (not directly translatable). Now there is at least one controlled dataset showing 48 weeks of weekly low-dose exposure without major signals.

3. Has any guideline body responded? No. As of mid-2026, no major medical society (AGS, Endocrine Society, AACE, or any national geriatrics body) has issued guidance on rapamycin for aging. The American Federation for Aging Research has acknowledged the trial but has not issued prescribing recommendations. PEARL is too small and too soft-endpoint-driven to trigger guideline changes on its own.

4. Does the trial population match real-world patients asking for this drug? Partially. The participants were health-conscious, predominantly well-educated, and self-selected from longevity communities. The median health status at baseline was already high. This limits generalizability in two directions: the modest improvements may not replicate in less health-optimized populations (ceiling effect in the trial cohort), and the safety profile may not hold in patients with comorbidities, polypharmacy, or metabolic syndrome.

Results that matter, in context

The quality-of-life improvements were domain-specific, not global. Participants did not uniformly feel better across all measures. Some domains showed improvement while others did not separate from placebo. This pattern is consistent with a real but modest signal rather than a significant clinical effect.

What PEARL did not answer

The trial leaves several critical questions unresolved. These are not minor gaps. They are the questions that would need answers before any responsible guideline update.

Duration of benefit. Forty-eight weeks is a start. Rapamycin's proposed mechanism for longevity involves autophagy upregulation, improved proteostasis, and immune remodeling. These processes operate on timescales of years, not months. Whether the quality-of-life signal persists, grows, or fades after year one is unknown.

Hard clinical endpoints. No infection data worth powering for. No cancer incidence. No cardiovascular events. No mortality. A trial of 114 people over 48 weeks cannot answer these questions, and PEARL was never designed to. But these are the endpoints that move clinical practice.

Dose optimization. PEARL tested two doses. The longevity clinic community uses a range of protocols: 1 mg daily, 3 mg weekly, 5 mg biweekly, 6 mg weekly with grapefruit juice to boost bioavailability. PEARL does not resolve which protocol, if any, is optimal. The Mannick et al. follow-up work on everolimus used different dosing entirely, making cross-study dose comparison difficult.

Drug interactions and comorbid populations. Rapamycin is a CYP3A4 substrate with significant interaction potential. The sirolimus prescribing information lists dozens of interactions. PEARL enrolled healthy adults on minimal medications. Patients asking longevity clinicians for rapamycin often take statins, metformin, antihypertensives, and supplements that may interact. No controlled data exist for these combinations at longevity doses.

What should change in practice today

Honestly? Very little at the institutional level. A great deal at the conversational level.

For clinicians already prescribing rapamycin off-label: PEARL provides the first controlled safety dataset to reference when discussing risk with patients. Before this trial, the conversation was "mouse data is strong, transplant data doesn't apply, and we have case series." Now it includes "a 48-week RCT of 114 healthy adults showed no serious adverse events at 5 or 10 mg weekly." That is a meaningful upgrade in informed consent quality, even if it does not constitute a prescribing indication.

For clinicians not prescribing rapamycin: PEARL does not create a reason to start. The evidence base remains pre-clinical plus one modest RCT with soft endpoints. The risk-benefit calculus for a healthy 55-year-old asking about rapamycin has shifted slightly toward "less risky than we feared" but has not moved on the "proven benefit" axis.

For patients: The trial confirms that weekly low-dose rapamycin is probably not dangerous over one year in healthy adults. It does not confirm that it extends lifespan, prevents disease, or produces benefits large enough to justify cost and monitoring. Patients should understand that taking rapamycin for longevity today remains an experiment on themselves, now with slightly better safety guardrails.

The larger evidence trajectory

PEARL sits within a growing body of early-phase longevity pharmacology research. The TRIMS trial examined topical rapamycin for skin aging. The Mannick everolimus studies examined immune function in older adults. The dog aging project has tested rapamycin in companion animals with mixed early results.

What is missing from the entire field is a large (N > 500), multi-year trial with hard endpoints. PEARL's value is that it makes such a trial more plausible by demonstrating acceptable safety and feasibility of recruitment. It is a stepping stone, not a destination.

Frequently asked questions

›Did PEARL prove rapamycin extends human lifespan?

No. PEARL measured quality-of-life domains, immune markers, and aging biomarkers over 48 weeks. It was not designed or powered to detect lifespan extension. Proving that would require thousands of participants followed for decades.

›What doses of rapamycin were used in PEARL?

Participants received either 5 mg or 10 mg of rapamycin (sirolimus) once per week, or matching placebo. This intermittent dosing protocol differs from the daily dosing used in transplant medicine and was chosen to selectively inhibit mTORC1 while minimizing mTORC2-related side effects.

›Were there serious side effects in the PEARL trial?

No serious adverse events were attributed to rapamycin in PEARL. Mouth ulcers occurred at low rates, consistent with known mucosal effects. Lipid and glucose levels remained stable. This is reassuring for the weekly dosing protocol but covers only 48 weeks.

›Has any medical society recommended rapamycin for longevity based on PEARL?

No. As of mid-2026, no major medical society has issued guidelines recommending rapamycin for anti-aging or longevity purposes. PEARL is considered a proof-of-concept safety study, not sufficient evidence for guideline-level recommendations.

›Who were the participants in the PEARL trial?

The 114 participants were generally healthy adults aged 50 to 85, recruited largely through longevity-focused communities. They were health-motivated and already tracking biomarkers, which limits generalizability to the broader older adult population.

›Can my doctor prescribe rapamycin based on PEARL results?

Rapamycin is FDA-approved for organ transplant immunosuppression and lymphangioleiomyomatosis, not for longevity. Physicians can prescribe it off-label, but PEARL alone does not establish an evidence-based indication. Patients considering off-label use should discuss the limited evidence and need for monitoring.

›How does PEARL compare to the Mannick everolimus studies?

The Mannick studies used a different rapalog (everolimus) at different doses and focused on immune response to vaccination. PEARL used rapamycin itself and measured broader quality-of-life and biomarker outcomes. Both suggest mTOR inhibition is tolerable in older adults, but they answer different clinical questions.

›What comes after PEARL in rapamycin research?

The field needs larger trials (N > 500) with longer follow-up (3 to 5 years) measuring hard endpoints like infection rates, cardiovascular events, and mortality. PEARL's contribution is showing that such trials are feasible and that weekly dosing has an acceptable safety profile for recruitment purposes.

›Should I stop or start rapamycin based on this trial?

PEARL should not prompt starting or stopping rapamycin on its own. For those already taking it, the trial provides modest reassurance about short-term safety at weekly doses. For those considering it, the trial does not demonstrate proven clinical benefit. Decisions should involve a physician familiar with the drug's monitoring requirements.

›Does PEARL apply to people with chronic conditions?

PEARL enrolled generally healthy adults with minimal medications. Its safety and efficacy findings should not be extrapolated to patients with diabetes, cardiovascular disease, autoimmune conditions, or those on multiple medications. Rapamycin's drug interaction profile is extensive, and no controlled data exist for these populations at longevity doses.

References

1. Kaeberlein M, et al. "Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL): a randomized clinical trial." Aging Cell. 2024. PubMed
2. Mannick JB, et al. "mTOR inhibition improves immune function in the elderly." Science Translational Medicine. 2014;6(268):268ra179. PubMed
3. Mannick JB, et al. "TORC1 inhibition enhances immune function and reduces infections in the elderly." Science Translational Medicine. 2018;10(449):eaaq1564. PubMed
4. FDA. Sirolimus (Rapamune) prescribing information. FDA Label
5. Harrison DE, et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature. 2009;460(7253):392-395. PubMed
6. Chung CL, et al. "Topical rapamycin reduces markers of senescence and aging in human skin." GeroScience. 2022. PubMed